Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ambrisentan for Treatment of Portopulmonary Hypertension (PoPH): a Pilot Study

NCT01733095 is registered in ClinicalTrials.gov with Medical University of Graz as lead sponsor.

NCT NCT01733095
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01733095 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ambrisentan for Treatment of Portopulmonary Hypertension (PoPH): a Pilot Study
Lead sponsor
Medical University of Graz
Phase
Phase 1/2
Overall status
Withdrawn
Start date
July 31, 2012
Completion date
June 30, 2016
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

portopulmonary hypertension